SILu™Prot CCL2 C-C motif chemokine 2 human
SIGMA/MSST0035 - SIL MS Protein Standard, 13C and 15N-labeled
Synonym: HC11; Monocyte chemoattractant protein 1; Monocyte chemotactic protein 1(MCP-1); Monocyte secretory protein JE; Monocytechemoattractantprotein1; Monocytechemotacticandactivatingfactor(MCAF); Small-inducible cytokine A2
Product Type: Chemical
SILuProt products are stable isotope-labeled full length proteins designed to be used as mass spectrometry internal standards for quantitative proteomics. Introduction of an internal SILuProt standard at the beginning of the MS workflow minimizes variations in quantification due to protein extraction, fractionation, enrichment, proteolysis and analysis
| assay | ≥98% (SDS-PAGE) |
| biological source | human |
| form | lyophilized powder |
| potency | ≥98% Heavy amino acids incorporation efficiency by MS |
| Quality Level | 200  |
| storage temp. | −20°C |
| suitability | suitable for mass spectrometry (standard) |
| technique(s) | mass spectrometry (MS): suitable |
| UniProt accession no. | P13500  |
| Biochem/physiol Actions: | SILu™Prot CCL2 is a recombinant, stable isotope-labeled human CCL2 which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of CCL2 in mass-spectrometry. SILu Prot CCL2 is a homodimer consisting of 96 amino acids (including C-terminal polyhistidine and FLAG® tags), with a calculated molecular mass of 11 kDa. |
| General description: | CCL2, the most thoroughly characterized CC chemokine, is a monocyte-specific chemoattractant that was demonstrated to attract T lymphocytes and NK cells, but not neutrophils. Enhanced expression of CCL2 was demonstrated in a variety of pathologic conditions, associated with inflammation and mononuclear cell infiltration. Extensive experimental evidence suggests that CCL2 is highly expressed in atherosclerotic plaques. In a recent study, CCL2 was shown to have value as a biomarker for risk stratification in both the initial and the chronic phases after an acute coronary syndromes (ACS). In contrast to CRP, CCL2 levels may be an indicator of long-term cardiovascular risk rather than a marker of acute prognosis. In urine, CCL2 levels were directly associated to Systemic Lupus Erythematosus disease activity, making it a non-invasive biomarker (avoiding blood sampling or tissue biopsies). |
| Immunogen: | QPDAINAPVTCCYNFTNRKISVQRL |
| Legal Information: | FLAG is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Legal Information: | SILu is a trademark of Sigma-Aldrich Co. LLC |
| Legal Information: | This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com. |
| Physical form: | Lyophilized from a solution of phosphate buffered saline. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 23201100 |